ABSTRACT
We saw in Chapter 1 that as the pharmaceuticals industry grew, so did the need for regulation. National drug authorities and local IRBs evolved as a consequence, with the protection of human wellbeing as their main remit. The advent of the ICH then provided a platform for international standardization of drug safety assessments between the major players — U.S., Japan, and the EU.
